Bio Pharma Dive

AUGUST 27, 2020

The approval for the FoundationOne Liquid CDx follows the agency's nod earlier this month for Guardant Health's next-generation sequencing diagnostic.

Medicine 294

Medicine Marketing 294

Drug Patent Watch

JANUARY 23, 2025

The Future of Generic Drug Development: Opportunities and Challenges for Emerging Markets As the global healthcare landscape continues to evolve, emerging markets are playing an increasingly important role in shaping the future of generic drug development. Share your thoughts in the comments below! Read the full article here: [link]

Generic Drugs 85

Generic Drugs Marketing Development Drugs 85

Pharmaceutical Technology

APRIL 3, 2023

The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilar Hyrimoz (adalimumab) citrate-free high-concentration formulation (HCF). The regulatory approval comes after a positive opinion was issued by the European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) in January this year.

Marketing 264

Marketing Medicine Packaging Packaging 264

Pharmaceutical Technology

MAY 21, 2024

Glenmark has entered into an exclusive agreement with BeiGene to market and distribute two Beigene oncology medicines in India.

Medicine 130

Medicine Marketing 130

Pharmaceutical Technology

APRIL 27, 2023

The European Commission’s (EC) long-anticipated pharma reform plans in the European Union have finally been unveiled , indicating a focus on improving access to medicines across the bloc while cutting down on market exclusivity. However, the reform has its share of critics. Applications will now be digitised.

Marketing 264

Marketing Medicine Production Clinical Trials 264

Bio Pharma Dive

JULY 9, 2021

Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.

Gene Therapy 269

Gene Therapy Gene Marketing Clinical Trials 269

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1]. .

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing 242

Marketing Production Branding Manufacturing 242

Bio Pharma Dive

OCTOBER 6, 2022

The pharma will invest in the biotech and co-promote its drug teplizumab if the FDA OKs the medicine as a first-of-its-kind diabetes treatment.

Drugs 277

Drugs Marketing Medicine 277

Bio Pharma Dive

APRIL 18, 2022

Early analysis of a key clinical trial showed a potentially increased risk of death in cancer patients who received a combination treatment that included TG Therapeutics' approved medicine, Ukoniq.

Clinical Trials 294

Clinical Trials Clinical Trials Marketing Medicine 294

Pharmaceutical Technology

JULY 7, 2022

But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine. It is certainly a pivotal moment for the cell and gene industry, with the next decade of R&D and clinical trials expected to transform the future of medicine. A new frontier in cancer research.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

World of DTC Marketing

APRIL 20, 2022

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. This was especially true with new drugs that have a significant competitive market. Will they transform their HCP marketing or stick to dated models?

Marketing 218

Marketing Drugs Drug Trials Sales 218

Bio Pharma Dive

JULY 11, 2024

Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the ultra-lucrative market for weight-loss medicines.

Medicine 312

Medicine Marketing Drugs 312

Bio Pharma Dive

AUGUST 2, 2024

Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.

Medicine 300

Medicine Marketing 300

Bio Pharma Dive

DECEMBER 14, 2021

Fitusiran, which Sanofi licensed from Alnylam, could finally get to market after trial delays and safety concerns slowed its progress. But gene therapies and other new medicines might provide competition.

Gene Therapy 323

Gene Therapy Licensing Licensing Gene 323

Bio Pharma Dive

OCTOBER 3, 2022

The regulator could soon approve medicines from Apellis, Gilead and GSK, as well as decide on whether to pull a controversial preterm birth drug from the market.

Regulation 318

Regulation Medicine Marketing Drugs 318

Bio Pharma Dive

DECEMBER 2, 2022

The approval gives Rigel, a biotech that’s been around since the mid-1990s, its second marketed medicine and a competitor to Servier’s Tibsovo.

Medicine 315

Medicine Drugs Marketing 315

Pharma Marketing Network

NOVEMBER 23, 2024

Just as a chef relies on quality ingredients for the perfect dish, marketers depend on cutting-edge research to craft campaigns that resonate with their audience. Just as a chef relies on quality ingredients for the perfect dish, marketers depend on cutting-edge research to craft campaigns that resonate with their audience.

Marketing 52

Marketing Research Big Data Medicine 52

Bio Pharma Dive

MARCH 3, 2022

As Aduhelm sputters on the market, Roche aims to prove its experimental medicine can work better. A large, multi-year trial is part of that bet.

Trials 310

Trials Medicine Drugs Marketing 310

Bio Pharma Dive

NOVEMBER 15, 2022

The approval makes Elahere the first wholly owned medicine the biotech has brought to market in its lengthy history.

Medicine 300

Medicine Drugs Marketing 300

Bio Pharma Dive

JULY 16, 2024

The well-funded startup says drugs AbbVie abandoned last year could form a combination regimen with “superior efficacy” to Vertex’s market-leading medicines.

Drugs 278

Drugs Medicine Marketing 278

Pharmaceutical Technology

MAY 22, 2023

The European Medicines Agency (EMA) has accepted and verified Sobi’s marketing authorisation application for a new factor VIII (FVIII), efanesoctocog alfa, to treat haemophilia A patients of all ages.

Marketing 217

Marketing Genetics Trials Medicine 217

Bio Pharma Dive

JUNE 2, 2021

Royalty Pharma will effectively fund MorphoSys' acquisition of the cancer biotech through a separate agreement to buy MorphoSys' shares of royalties on several marketed and experimental medicines.

Medicine 301

Medicine Marketing 301

Bio Pharma Dive

AUGUST 5, 2024

For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical.

Branding 258

Branding Manufacturing Medicine Marketing 258

Bio Pharma Dive

JULY 29, 2022

Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

Sales 286

Sales Medicine Drugs Marketing 286

Bio Pharma Dive

AUGUST 10, 2022

The biotech’s failed attempt to develop an eye disease drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets.

Medicine 293

Medicine Marketing Development Drugs 293

Bio Pharma Dive

AUGUST 23, 2022

The biotech successfully brought two medicines to market, but shares have lost most of their value amid sluggish sales.

Sales 278

Sales Medicine Drugs Marketing 278

Bio Pharma Dive

OCTOBER 26, 2022

It joins a group of medicines on market that target a protein called BCMA. The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease.

Protein 290

Protein Antibody Medicine Drugs 290

Bio Pharma Dive

MARCH 23, 2023

The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.

Antibody 286

Antibody Trials Medicine Marketing 286

Bio Pharma Dive

AUGUST 29, 2023

A broadened clearance for Reblozyl in myelodysplastic syndromes should help Bristol Myers offset the looming loss of revenue from top-selling medicines set to soon lose market exclusivity.

FDA Approval 286

FDA Approval Medicine Drugs Marketing 286

Bio Pharma Dive

SEPTEMBER 21, 2021

Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.

FDA Approval 285

FDA Approval Drugs Antibody Medicine 285

Pharmaceutical Technology

AUGUST 30, 2022

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

Manufacturing 195

Manufacturing Marketing Pharma Companies Vaccination 195

Pharmaceutical Technology

MAY 30, 2023

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. We are confident it will be the milestone to solidify our position in the global market amid the transition of the pandemic to the endemic phase.”

Vaccine 298

Vaccine Vaccination Protein Medicine 298

Bio Pharma Dive

AUGUST 12, 2021

The decision, which does provide for certain exceptions, is another bump in what's become a rocky market rollout for Biogen's medicine.

Medicine 258

Medicine Drugs Marketing 258

Bio Pharma Dive

MARCH 25, 2025

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed geographic atrophy medicines.

Medicine 195

Medicine Drugs Marketing 195

XTalks

MARCH 10, 2025

The FDA has approved Genentechs TNKase (tenecteplase) for the treatment of acute ischemic stroke in adults, marking a milestone as the first new stroke medicine approved in nearly three decades.

Medicine 59

Medicine Trials Pharmacy Clinical Trials 59

Pharmaceutical Technology

MAY 5, 2023

The European Medicines Agency’s (EMA) committee for medicinal products for human use (CHMP) has recommended full marketing authorisation (MA) for Gilead Sciences ’ Hepcludex (bulevirtide) to treat chronic hepatitis delta virus (HDV) and compensated liver disease in adult patients.

Marketing 147

Marketing Medicine Drugs Production 147